X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (738) 738
Publication (150) 150
Patent (73) 73
Paper (48) 48
Book / eBook (13) 13
Book Chapter (5) 5
Conference Proceeding (4) 4
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (423) 423
index medicus (278) 278
female (206) 206
male (192) 192
oncology (181) 181
pathology (174) 174
middle aged (159) 159
cancer (156) 156
immunohistochemistry (153) 153
prognosis (152) 152
aged (139) 139
adult (123) 123
tumors (118) 118
expression (100) 100
aged, 80 and over (92) 92
610 medicine & health (89) 89
institute of pathology and molecular pathology (89) 89
physics (83) 83
kidney neoplasms - pathology (77) 77
kidney neoplasms - genetics (75) 75
carcinoma (68) 68
carcinoma, renal cell - genetics (67) 67
neoplasm staging (67) 67
analysis (62) 62
animals (61) 61
carcinoma, renal cell - pathology (61) 61
mutation (61) 61
genetic aspects (60) 60
research (59) 59
tissue array analysis (57) 57
cell line, tumor (52) 52
experiment (50) 50
surgery (50) 50
in situ hybridization, fluorescence (48) 48
kidney neoplasms - metabolism (48) 48
particle physics (48) 48
high energy physics - experiment (47) 47
mice (47) 47
cell biology (46) 46
physics - high energy physics - experiment (45) 45
carcinoma, renal cell - metabolism (44) 44
chemistry (44) 44
metallurgy (44) 44
breast cancer (43) 43
breast-cancer (43) 43
identification (43) 43
metastasis (43) 43
survival (42) 42
gene expression regulation, neoplastic (41) 41
prostate cancer (41) 41
biomarkers, tumor - metabolism (40) 40
diagnosis (38) 38
gene expression (38) 38
kaplan-meier estimate (37) 37
renal cell carcinoma (37) 37
retrospective studies (37) 37
biomarkers, tumor - analysis (36) 36
genes (36) 36
research article (36) 36
blasting (35) 35
heating (35) 35
lighting (35) 35
mechanical engineering (35) 35
proteins (35) 35
weapons (35) 35
comparative genomic hybridization (34) 34
survival rate (34) 34
testing (34) 34
investigating or analysing materials by determining theirchemical or physical properties (33) 33
measuring (33) 33
mutations (32) 32
high energy physics (31) 31
human necessities (31) 31
medicine & public health (31) 31
peptides (31) 31
combined heating and refrigeration systems (30) 30
gene (30) 30
heat pump systems (30) 30
hygiene (30) 30
liquefaction solidification of gases (30) 30
manufacture or storage of ice (30) 30
medical or veterinary science (30) 30
organic chemistry (30) 30
preparations for medical, dental, or toilet purposes (30) 30
prostatic neoplasms - pathology (30) 30
refrigeration or cooling (30) 30
classification (29) 29
tissue microarray (29) 29
urology & nephrology (29) 29
amplification (28) 28
breast neoplasms - pathology (28) 28
immunotherapy (28) 28
prostate-cancer (28) 28
fysik (27) 27
genetics (27) 27
metastases (27) 27
physical sciences (27) 27
predictive value of tests (27) 27
specific therapeutic activity of chemical compounds ormedicinal preparations (27) 27
urologic and male genital diseases (27) 27
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (7) 7
UTL at Downsview - May be requested (3) 3
St. Michael's College (John M. Kelly) - 2nd Floor (2) 2
Art - Library use only (1) 1
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Music - Stacks (1) 1
Online Resources - Online (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (795) 795
German (59) 59
French (37) 37
Chinese (4) 4
Portuguese (4) 4
Spanish (3) 3
Celtic (1) 1
Danish (1) 1
Hungarian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2016, 4th edition., World Health Organization classification of tumours, ISBN 9789283224372, 356 pages
Book
Journal Article
International Journal of Cancer, ISSN 0020-7136, 07/2016, Volume 139, Issue 2, pp. 396 - 403
In our study, we demonstrate that ccRCC cell lines with impaired function of pVHL to degrade HIFα express elevated levels of PD‐L1. In vitro analysis provided... 
ccRCC | HIF | pVHL | PD‐L1 | PD-L1 | CANCER-CELLS | PATHWAYS | ANTIBODY | IDENTIFICATION | HIF1-ALPHA | ESCAPE | TUMOR-SUPPRESSOR PVHL | THERAPY | ONCOLOGY | MUTATIONS | BLOCKADE | Immunohistochemistry | Gene Expression | Kidney Neoplasms - genetics | Hypoxia-Inducible Factor 1, alpha Subunit - genetics | Humans | Gene Expression Regulation, Neoplastic | Gene Silencing | Carcinoma, Renal Cell - genetics | Kidney Neoplasms - metabolism | B7-H1 Antigen - genetics | Case-Control Studies | Carcinoma, Renal Cell - metabolism | B7-H1 Antigen - metabolism | B7-H1 Antigen - blood | Hypoxia-Inducible Factor 1, alpha Subunit - metabolism | Cell Line, Tumor | Von Hippel-Lindau Tumor Suppressor Protein - genetics | Mutation | Analysis | Cancer | Chemotherapy | Rodents | Kidney cancer | Hypoxia | Ligands | T cell receptors | Apoptosis | Drugs | Biotechnology | Hypoxia-inducible factor 1 | Correlation | Target recognition | PD-1 protein | Genes | Lymphocytes T | In vitro testing | Drug delivery | Inactivation | Immunosuppressive agents | Degradation | Inhibition | Hypoxia-inducible factors | Deactivation | Mortality | Immunosurveillance | Tumor cell lines | Patients | Surveillance | Cell death | PD-L1 protein | Reagents | VHL protein | Aberration | Neoplasia | Clear cell-type renal cell carcinoma | Tumors | Kidney transplantation
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 11/2010, Volume 124, Issue 2, pp. 497 - 507
Trastuzumab has conferred significant clinical benefits in HER-2-positive breast carcinomas. HER-2 status is determined by immunohistochemistry (IHC) and/or... 
Medicine & Public Health | Cost–effectiveness | Oncology | Adjuvant | Breast cancer | Predictive tests | Trastuzumab | Cost-effectiveness | ADJUVANT CHEMOTHERAPY | 1ST-LINE TREATMENT | EFFICACY | SAFETY | PROGNOSIS | MONOCLONAL-ANTIBODY | DOCETAXEL | HER-2 STATUS | LOCAL RECURRENCE | ONCOLOGY | TRASTUZUMAB THERAPY | Drug Costs | Predictive Value of Tests | Markov Chains | Receptor, ErbB-2 - genetics | Humans | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Models, Economic | Mass Screening - methods | Antibodies, Monoclonal, Humanized | Breast Neoplasms - chemistry | Sensitivity and Specificity | Female | Chemotherapy, Adjuvant | Immunohistochemistry - economics | Quality-Adjusted Life Years | In Situ Hybridization, Fluorescence - economics | Biomarkers, Tumor - analysis | Mass Screening - economics | National Health Programs - economics | Treatment Outcome | Breast Neoplasms - drug therapy | Switzerland | Antineoplastic Agents - economics | Health Care Costs | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Cost-Benefit Analysis | Biomarkers, Tumor - genetics | Receptor, ErbB-2 - analysis | Antibodies, Monoclonal - economics | Immunohistochemistry | Cancer patients | Epidermal growth factor | Analysis | Adjuvant treatment | Economic aspects | Fluorescence | Cost benefit analysis | Cancer
Journal Article